$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple MyelomaPRNewsWire · 6 days ago
Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL)Defense World · Oct 6, 2026
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial ResultsPRNewsWire · Sep 30, 2026
Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)Defense World · Sep 21, 2026
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®PRNewsWire · Sep 1, 2026
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth OpportunitiesPRNewsWire · Aug 31, 2026RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 5, 2025 | -$690.00 | -$1.00 | Beat |
| Apr 10, 2025 | -$690.00 | -$1.00 | Beat |
| Oct 3, 2024 | -$690.00 | -$1.00 | Beat |
| Jul 30, 2024 | -$0.30 | -$2.00 | Miss |
| Apr 8, 2024 | – | -$1.00 | |
| Mar 14, 2024 | -$0.03 | -$0.20 | Miss |